Richmond Pharmacology presents further QT insulin data next month in San Diego!

Posted:
30
August 2012

30th August 2012

Richmond Pharmacology presents further QT insulin data next month in San Diego!

We welcome you to attend the 2012 Annual Meeting of the American College of Clinical Pharmacology (ACCP), taking place 23rd-25th September, at the Sheraton San Diego Hotel & Marina.This topic of this year's meeting is  Translating Clinical Pharmacology Research into Optimized Patient Care  and will encompass a series of Pre-meeting Workshops and Symposia on related content such as the role of clinical pharmacology in speeding the development of new anti-infective drugs to combat drug resistance, pharmacometrics in hospital-based pharmacotherapy, innovations in drug therapies, and much more.Join Richmond Pharmacology on Day 1, Sun 23rd Sep between 6 and 8pm, where we will present further data on studies using techniques such as the euglycaemic insulin clamp to probe the effect of insulin on the QT interval in healthy Caucasian and Japanese volunteers:

  • Late changes after a euglycaemic insulin clamp can lead to significant increases in QTcF in healthy subjects
  • The impact of insulin levels on QTc interval in Thorough QT studies conducted in healthy subjects

View full program

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more